Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Adaptimmune Therapeutics Stock Price, Quotes and Forecasts
ADAPNASDAQ
Adaptimmune Therapeutics (ADAP) Forecast
NewsEarningsAdaptimmune Therapeutics (ADAP) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestEdge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Adaptimmune Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ADAP | Benzinga
Explore Adaptimmune Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ADAP.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Adaptimmune Therapeutics (ADAP) stock?
You can purchase shares of Adaptimmune Therapeutics (NASDAQ:ADAP) through any online brokerage.
Who are Adaptimmune Therapeutics (ADAP) competitors?
Other companies in Adaptimmune Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Skye Bioscience (NASDAQ:SKYE), Inovio Pharmaceuticals (NASDAQ:INO), Vistagen Therapeutics (NASDAQ:VTGN) and Adagene (NASDAQ:ADAG).
What is the forecast, or price target, for Adaptimmune Therapeutics (ADAP) stock?
Adaptimmune Therapeutics has a consensus price target of $3.54.
What is the current price for Adaptimmune Therapeutics (ADAP)?
The stock price for Adaptimmune Therapeutics (NASDAQ: ADAP) is $0.304 last updated March 24, 2025 at 9:41 AM EDT.
Does Adaptimmune Therapeutics (ADAP) pay a dividend?
There are no upcoming dividends for Adaptimmune Therapeutics.
When is Adaptimmune Therapeutics (NASDAQ:ADAP) reporting earnings?
Adaptimmune Therapeutics’s Q1 earnings are confirmed for Wednesday, May 14, 2025.
Is Adaptimmune Therapeutics (ADAP) going to split?
There is no upcoming split for Adaptimmune Therapeutics.
What sector and industry does Adaptimmune Therapeutics (ADAP) operate in?
Adaptimmune Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.